To this end, human samples from controls or patients with liver cirrhosis from nonalcoholic steatohepatitis were assayed since cirrhosis is associated with angiogenesis [35], and since FGF21 has been previously implicated in steatohepatitis liver injury pathways [12]. Here, FGF21 is linked to metabolic dysfunction-associated steatohepatitis.